Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.

Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, Thielke A, Aster JC, Regev A, Ebert BL
Nat Biotechnol. 2014 Jun 22. doi: 10.1038/nbt.2951. PubMed Article

Plasmids from Article

ID	Plasmid	Purpose
57818	pL-CRISPR.EFS.GFP	Lentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA. Coexpresses eGFP via P2A cleavage site. EFS Promoter driven
57821	pLKO5d.EFS.SpCas9.P2A.BSD	Lentiviral Vector for SpCas9 Expression without sgRNA, Blasticidin resistance, EFS Promoter driven
57822	pLKO5.sgRNA.EFS.GFP	3rd generation lentiviral Vector for Sp sgRNA delivery without SpCas9, GFP, EFS Promoter driven
57823	pLKO5.sgRNA.EFS.tRFP	3rd generation Lentiviral Vector for Sp sgRNA delivery without SpCas9, tagRFP, EFS Promoter driven
57824	pLKO5.sgRNA.EFS.tRFP657	Lentiviral Vector for Sp sgRNA delivery without SpCas9, tagRFP657, EFS Promoter driven
57825	pLKO5.sgRNA.EFS.PAC	Lentiviral Vector for Sp sgRNA delivery without SpCas9, Puromycin resistance, EFS Promoter driven
57826	pL-CRISPR.SFFV.tRFP	Lentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA. Coexpresses tagRFP via P2A cleavage site. SFFV Promoter driven
57827	pL-CRISPR.SFFV.GFP	Lentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA. Coexpresses eGFP via P2A cleavage site. SFFV Promoter driven
57828	pL-CRISPR.EFS.PAC	Lentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA, Puromycin resistance, EFS Promoter driven
57829	pL-CRISPR.SFFV.PAC	Lentiviral CRISPR-Cas9 delivery for SpCas9 and sgRNA, Puromycin resistance, SFFV Promoter driven
58329	pLKO5d.EFS.SpCas9.P2A.PAC	Lentiviral Vector for SpCas9 Expression without sgRNA, Puromycin resistance, EFS Promoter driven
61395	pL-SFFV.Reporter.RFP657.PAC	Lentiviral vector for RFP657 NHEJ reporter system expression. Allows insertion of target sites between the SFFV promoter and RFP657 for detection of fluorescence knockdown. Puromycin resistance.